Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TR115 in ARID1A-mutated advanced solid tumors
ChiCTR2600132021Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TR115 in clear cell ovarian cancer, fallopian tube clear cell adenocarcinoma, Clear Cell Primary Peritoneal Carcinoma (PPCCC) and 4 more (3 cohorts), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
TR115
03
Conditions
clear cell ovarian cancerfallopian tube clear cell adenocarcinomaClear Cell Primary Peritoneal Carcinoma (PPCCC)endometrial cancer (EC)gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2600132021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132021.